Trials, pilots, and research are now happening in months.Bio's pipeline of research projects is rapidly advancing. Track scientific progress across decentralized biotechs in the Bio Network. Apply to launch a project with Bio → b̲i̲o̲.̲x̲yz̲/̲s̲c̲i̲e̲n̲t̲i̲s̲t̲s̲See below the latest scientific updates in the Bio Ne...
New projects in mitochondrial biology and aging pathways are launching this quarter.
Cerebrum DAO: Progress across five active neuroscience programs:
• Percepta: The clinical study protocol is finalized, and the IRB has been resubmitted with the pTau-217 biomarker.
Newsletter
Get the latest updates from the Bio ecosystem
New launches, research progress, and ways to get involved across the Biosphere.
• FissionBio: Mitochondrial ROS inhibitors have been validated in the first screen, and a second assay is currently underway.
• Transfidelity: The alpha-synuclein fidelity study is exceeding milestones, and a review has been accepted in Neural Regeneration Research.
• SK Channels: The replication study is completed, and we are evaluating next steps following mixed results.
𝗨𝗽𝗰𝗼𝗺𝗶𝗻𝗴: @NEURONGale project explores Galectin-3 inhibition as a novel Alzheimer’s therapy. Dr. Tomas Deierborg, Prof. of Neuroinflammation at Lund University, will lead testing of a small molecule in an in vivo mouse model, aiming to open a new path in Central Nervous System drug discovery.
PsyDAO: Formalized IP and governance frameworks for psychedelic science and advanced numerous proposals through expert review and funding:
• Endo-DMTx (endogenous DMT pathway) led by Andrew Gallimore, Noonnautics & Dr. Chris McCurdy(university of florida, college of pharmacy)
• BABS UCSF (human MRI study with Prof. Carhart-Harris): targeting high‐impact human data on enduring brain changes post‐first psilocybin use.
ValleyDAO: Hempy enzyme platform has achieved lab-scale validation for hemp fiber treatment and is now preparing patent filings for two enzyme-based processes.
• Cocoa Zero and KardaForge programs have advanced toward pilot-scale testing for sustainable fats and metal recovery.
Next: patent filings this quarter and expanded IP Token integration via the Phlo AI research platform.
Curetopia: Led by Dr. Ethan Perlstein and Paula Vujic, Curetopia advanced its ARS drug-repurposing pipeline using yeast-based screens.
Hit validation and animal studies are underway, with DAO-to-company translational pilots expected in 2026.
HairDAO: Has completed several preclinical studies including:
• TRH Topical and Topical Thyroid Hormones have both been finalized and filed for provisional patents.
• The Dutasteride Delivery Vehicle, an optimized topical formulation, is nearing launch on Anagen.xyz.
• Twist1 and the in-house Olanzapine/Farnesol are progressing toward observational human studies.
HairDAO continues to integrate wet-lab R&D with its Anagen telehealth platform for data collection.
AthenaDAO: Advanced four women’s health programs this year:
• FACC: A fertility small-molecule inhibitor showing in-vivo efficacy and improved metabolism in aged mice.
• OVARIA: An AI model predicting menopause transition risk, trained on UK Biobank data.
• ISR: Ovarian stress-response target validation is underway.
• LifeAhead: A spin-out has been formed; a provisional patent has been filed, and a pre-seed raise is in preparation. Proof-of-concept data is expected in Q4 2025–Q1 2026.
Quantum Biology DAO: The Quantum Microscope project has completed instrument assembly and started magnetosensitivity experiments on engineered proteins.
A FAIR data pipeline and a public whitepaper are scheduled for early 2026.
The treasury surpasses $4.3M USD, providing a 30-month runway.
𝗧𝗵𝗲 𝗴𝗼𝗮𝗹: move science from experimentation to application faster & cheaper than legacy biotech.
Accelerating R&D across longevity, brain health, fertility, skin care & more.
